non-holder here doing some DD: anyone has thoughts on the Ph 2 efficacy data for proteinuria comparing to the CSL Vifor data for sparsentan? DMX200 looks inferior to me and if sparsentan had issues meeting the primary endpoint in a Ph 3 why would DMX200 succeed?
non-holder here doing some DD: anyone has thoughts on the Ph 2...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.035(8.24%) |
Mkt cap ! $214.3M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 41.5¢ | 38.5¢ | $5.166M | 12.97M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 152733 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 20060 | 2 |
View Market Depth
| Last trade - 16.10pm 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
39.0¢ |
Change
-0.035 ( 7.80 %) |
||||
| Open | High | Low | Volume | ||
| 41.0¢ | 41.5¢ | 38.5¢ | 8440248 | ||
| Last updated 15.59pm 28/05/2024 ? | |||||
| DXB (ASX) Chart |